Clinical Trials Browser

INDUSTRY × luspatercept × Clear all

NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3 Recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT04717414 2025-07-10

INDEPENDENCE

Phase 3 Active not recruiting

Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01688011 2025-07-03

Connect® Myeloid Disease Registry

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Phase 2 Completed

95 enrolled 32 charts

Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

NCT02604433 2023-04-18

BELIEVE

Phase 3 Completed

336 enrolled 38 charts 1 FDA

beta-Thalassemia

NCT02631070 2021-12-17

MEDALIST

Phase 3 Completed

229 enrolled 36 charts 2 FDA

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes